研究人员报告在开发安全有效的新冠病毒疫苗方面取得了进展。这种病毒导致的新冠肺炎已经在全球造成至少61万人死亡。还有超过1470万人被感染。
Two different experimental vaccines have produced strong immune reactions in people involved in the studies. And neither produced serious unwanted effects. The separate research was published Monday in the British medical journal The Lancet.
两种不同的实验性疫苗在志愿者当中产生了强烈的免疫反应。两者均未产生严重的不良影响。这项独立研究周一发表在英国《柳叶刀》医学杂志上。
The most promising of the two preventative medicines comes from a partnership between Oxford University in Britain and drug maker AstraZeneca. The company has signed agreements with many governments to supply its vaccine if it proves to be effective and wins legal approval. AstraZeneca has promised to make 2 billion vaccine treatments.
两种预防性疫苗中最有成效的疫苗来自于牛津大学和阿斯利康制药公司之间的合作。该公司已经与许多政府签署协议，如果其疫苗被证实有效并获得法律批准就投入使用。阿斯利康公司已经承诺生产20亿支疫苗。
The New York Times newspaper reports that the vaccine has been given to more than 10,000 volunteers in Britain, Brazil and South Africa. It says 30,000 people in the United States are to receive the experimental vaccine next week.
《纽约时报》报道称，已经给英国、巴西和南非的1万多名志愿者接种了这种疫苗。该报道称 下周将有3万美国人接种这种实验性疫苗。
The drug company CanSinoBiologics Incorporated and the Chinese military is developing the other vaccine. It was tested on 508 healthy volunteers who received one treatment each, the researchers reported. Most of those tested showed a good immune reaction.
康希诺生物股份公司和中国军方正在研发另一种疫苗。研究人员报告称，已经对508名健康志愿者进行了测试。大多数测试者显示出了良好的免疫反应。
About 77 percent of the volunteers reported temporary side effects, including increased body temperature and pain at the place of injection. None of the side effects were severe or unusual, the researchers reported.
大约77%的志愿者报告了暂时的副作用，包括体温升高和注射部位疼痛。研究人员报告称，没有发生严重或异常的副作用。
Both the AstraZeneca and CanSino vaccines use a harmless adenovirus to carry genetic material from the new coronavirus into the body.
阿斯利康和康希诺的疫苗都使用了无害的腺病毒将来自于新冠病毒的基因注入体内。
"Overall, the results of both trials are broadly similar and promising," Naor Bar-Zeev and William Moss wrote in The Lancet. Both writers are vaccine experts at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
Naor Bar-Zeev和William Moss在柳叶刀杂志上写道：“总体而言， 这两项试验的结果大致相同并且颇有希望。”这两位作者是马里兰州巴尔的摩市霍普金斯大学彭博公共卫生学院的疫苗专家。
Also Monday, the drug maker Pfizer and its partner BioNTech reported success on their vaccine candidate. That study was small, involving 60 healthy adults. Outside experts have not yet examined the research findings.
同样是在周一，辉瑞制药公司及其合作伙伴BioNTech报告了他们的候选疫苗获得成功。该研究规模很小，仅涉及60名健康成年人。外部专家尚未对这项研究结果进行检查。
Last week, the medical research company Moderna announced strong immune reaction in tests of a vaccine developed by researchers at the U.S. National Institute of Allergy and Infectious Diseases. However, the volunteers involved in that research reported more unwanted effects such as tiredness, head pain, chills and muscle pain.
上周，Moderna医学研究公司宣布，由美国国家过敏和传染病研究所的研究人员开发的疫苗在测试中产生了很强的免疫反应。 但是，参与该研究的志愿者报告了更多的不良反应，例如疲劳、头痛、发冷和肌肉疼痛。
Dr. Peter Hotez is an infectious diseases expert at Baylor College of Medicine in Houston, Texas. On Monday, he told the American news group CNN that "the first vaccines may not be our best vaccines." Hotez said it would probably take another year to produce all the necessary evidence that the new coronavirus vaccines are safe and effective.
Peter Hotez博士是德克萨斯州休斯顿贝勒医学院的传染病专家。他周一对美国有线电视网表示，“首批疫苗可能不是我们最好的疫苗。”Hotez表示，可能还要一年时间才能得出所有必要证据，来证实新冠病毒疫苗是安全有效的。
Early Tuesday, European leaders agreed on a $2.1-trillion budget. The agreement includes $857 billion in coronavirus support that will be issued as loans and aid to the hardest-hit countries.
周二早些时候，欧洲领导人达成了2.1万亿美元的预算。该协议包括提供8570亿美元的新冠病毒援助，这将作为对受疫情影响最严重国家的贷款和援助。
I'm Caty Weaver.
我是凯蒂·韦孚。(51VOA.COM原创翻译，禁止转载，违者必究！)